

October 20, 2010

Ei Yamada, President and CEO
AnGes MG, Inc.

(Code No.4563, TSE Mothers)

Contact: Fumihiko Suzuki, Director, Corporate Planning Dept.

Tel: +81-3-5730-2480

FOR IMMEDIATE RELEASE

Development of Novel Disinfectant Utilizing Antimicrobial Peptide “Cure-Peptin” through
Joint R&D Efforts with Morishita Jintan Co., Ltd.

AnGes MG, Inc. and Morishita Jintan Co., Ltd. have been working together with the aim of developing new products based on functional peptides with antimicrobial activity, named “Cure-peptin”. AnGes MG is pleased to announce that the companies have successfully developed a disinfectant, containing a peptide with superior antimicrobial activity than that of conventional antimicrobial agents.

AnGes MG has been developing novel disinfectants with long-lasting effects containing a peptide with superior antimicrobial activity than that of conventional antimicrobial agents that can be used in places such as operating rooms. This antimicrobial agent has broad spectrum of activity against gram-negative bacteria, gram-positive bacteria, fungi, etc. The agent is effective against not only the widely-publicized infectious bacteria such as *Escherichia coli*, *Pseudomonas aeruginosa*, *Trichophyton*, etc., but also against multiple-drug-resistant bacteria, such as MRSA, which are major problem with nosocomial infections. Additionally, the agent is effective against *Acinetobacter* (Refer to Note), which has become an issue due to some recently reported fatal cases. It also demonstrated efficacy against influenza viruses. Based on these findings, the agent is expected to have wide-ranging antimicrobial/antiviral effects. Further, it was found that the emergence of resistant bacteria to this agent is highly unlikely and that the agent has a higher level of safety compared to other disinfectants which have been used to date. Considering these findings comprehensively, it is expected that the agent can be differentiated, as a novel disinfectant, from the conventional products.

Regarding the concept as a commercial product, wide-ranging applications will be strategically pursued, from an environmental disinfectant for routine use to a long-acting novel disinfectant for use in the operating rooms.

These results represent the fruits of a project adopted and implemented as the “Innovation Promotion Project (March 06, 2009 - March 20, 2010)” supported by the New Energy and Industrial Technology Development Organization of Japan.

There will be no effect of this development on AnGes MG’s business performance during the current fiscal year.

Note) Because there is no clear definition of resistant strains of *Acinetobacter*, this refers to efficacy against the standard strain.

[Reference]

Company name:	Morishita Jintan Co., Ltd.
Head office:	1-2-40 Tamatsukuri, Chuo-ku, Osaka
Representative:	Junichi Komamura, Representative Director & President
Established:	November 1936
Capital:	3,537 million yen (end of March 2010)
Number of employees:	231 (end of March 2010)
Consolidated sales:	7,492 million yen (term ending March 2010)
Scope of business:	Manufacture and distribution of medicines, quasi-medicines, medical devices, food products, etc.

###